Current and historical daily PE Ratio for BeiGene Ltd (
HKSE:06160
) from 2018 to Apr 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. BeiGene stock (HKSE:06160) PE ratio as of Apr 19 2024 is 0.
More Details
BeiGene Ltd (HKSE:06160) PE Ratio (TTM) Chart
BeiGene Ltd (HKSE:06160) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1189
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| BeiGene PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-20 | At Loss | 2024-02-14 | At Loss |
| 2024-04-19 | At Loss | 2024-02-09 | At Loss |
| 2024-04-18 | At Loss | 2024-02-08 | At Loss |
| 2024-04-17 | At Loss | 2024-02-07 | At Loss |
| 2024-04-16 | At Loss | 2024-02-06 | At Loss |
| 2024-04-15 | At Loss | 2024-02-05 | At Loss |
| 2024-04-12 | At Loss | 2024-02-02 | At Loss |
| 2024-04-11 | At Loss | 2024-02-01 | At Loss |
| 2024-04-10 | At Loss | 2024-01-31 | At Loss |
| 2024-04-09 | At Loss | 2024-01-30 | At Loss |
| 2024-04-08 | At Loss | 2024-01-29 | At Loss |
| 2024-04-05 | At Loss | 2024-01-26 | At Loss |
| 2024-04-03 | At Loss | 2024-01-25 | At Loss |
| 2024-04-02 | At Loss | 2024-01-24 | At Loss |
| 2024-03-28 | At Loss | 2024-01-23 | At Loss |
| 2024-03-27 | At Loss | 2024-01-22 | At Loss |
| 2024-03-26 | At Loss | 2024-01-19 | At Loss |
| 2024-03-25 | At Loss | 2024-01-18 | At Loss |
| 2024-03-22 | At Loss | 2024-01-17 | At Loss |
| 2024-03-21 | At Loss | 2024-01-16 | At Loss |
| 2024-03-20 | At Loss | 2024-01-15 | At Loss |
| 2024-03-19 | At Loss | 2024-01-12 | At Loss |
| 2024-03-18 | At Loss | 2024-01-11 | At Loss |
| 2024-03-15 | At Loss | 2024-01-10 | At Loss |
| 2024-03-14 | At Loss | 2024-01-09 | At Loss |
| 2024-03-13 | At Loss | 2024-01-08 | At Loss |
| 2024-03-12 | At Loss | 2024-01-05 | At Loss |
| 2024-03-11 | At Loss | 2024-01-04 | At Loss |
| 2024-03-08 | At Loss | 2024-01-03 | At Loss |
| 2024-03-07 | At Loss | 2024-01-02 | At Loss |
| 2024-03-06 | At Loss | 2023-12-29 | At Loss |
| 2024-03-05 | At Loss | 2023-12-28 | At Loss |
| 2024-03-04 | At Loss | 2023-12-27 | At Loss |
| 2024-03-01 | At Loss | 2023-12-22 | At Loss |
| 2024-02-29 | At Loss | 2023-12-21 | At Loss |
| 2024-02-28 | At Loss | 2023-12-20 | At Loss |
| 2024-02-27 | At Loss | 2023-12-19 | At Loss |
| 2024-02-26 | At Loss | 2023-12-18 | At Loss |
| 2024-02-23 | At Loss | 2023-12-15 | At Loss |
| 2024-02-22 | At Loss | 2023-12-14 | At Loss |
| 2024-02-21 | At Loss | 2023-12-13 | At Loss |
| 2024-02-20 | At Loss | 2023-12-12 | At Loss |
| 2024-02-19 | At Loss | 2023-12-11 | At Loss |
| 2024-02-16 | At Loss | 2023-12-08 | At Loss |
| 2024-02-15 | At Loss | 2023-12-07 | At Loss |
BeiGene Ltd (HKSE:06160) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
BeiGene Ltd
NAICS : 325412
SIC : 2834
ISIN : KYG1146Y1017
Share Class Description:
HKSE:06160: Ordinary SharesCompare
Compare
Traded in other countries / regions
688235.China06160.Hong KongBGNE.USA49B.GermanyB1GN34.BrazilBGNE.Mexico IPO Date
2018-08-08Description
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers